Exposure-Guided Dose Optimization in Complex Acute Care

Abstract

Exposure-guided dose optimization is an evolving strategy in acute care medicine, aiming to individualize pharmacotherapy in the context of complex and critically ill patients. This approach leverages pharmacokinetic and pharmacodynamic (PK/PD) principles, real-time drug monitoring, and patient-specific variables to maximize therapeutic efficacy while minimizing toxicity. This review synthesizes current evidence, clinical guidelines, and practical considerations for implementing exposure-guided dosing in acute care, highlighting its impact on outcomes, mechanisms, and future potential in the management of critically ill patients.

Introduction

Acute care settings, particularly intensive care units (ICUs), present unique challenges for drug dosing due to the heterogeneity and rapidly changing physiology of critically ill patients. Standard dosing regimens, often derived from non-critical populations, may result in suboptimal exposure, increased toxicity, or therapeutic failure. Exposure-guided dose optimization, which tailors drug dosing based on measured or predicted drug concentrations and individual PK/PD targets, is gaining traction as a means to improve patient outcomes. This article provides a comprehensive review of the scientific rationale, clinical relevance, and practical implementation of exposure-guided dose optimization in complex acute care environments.

Epidemiology / Disease Burden

The burden of suboptimal drug exposure in acute care is substantial. Studies indicate that up to 60% of critically ill patients may experience inadequate drug concentrations when standard dosing is employed, contributing to increased morbidity, prolonged hospital stays, and higher healthcare costs. Antimicrobials, anticoagulants, sedatives, and vasoactive agents are among the most commonly implicated drug classes. The growing prevalence of drug-resistant infections and an aging population with multimorbidity further amplify the need for precise dosing strategies in acute care.

Pathophysiology

Critical illness induces profound alterations in drug absorption, distribution, metabolism, and excretion. Factors such as altered organ perfusion, capillary leak syndrome, fluid shifts, hypoalbuminemia, renal and hepatic dysfunction, and the use of extracorporeal support devices (e.g., ECMO, CRRT) complicate the prediction of drug exposure. These pathophysiological changes can lead to both underdosing risking therapeutic failure and overdosing risking toxicity. A mechanistic understanding of these processes is crucial for implementing exposure-guided dosing in the acute care context.

Risk Factors

Several patient- and treatment-related factors increase the risk of altered drug exposure in acute care. These include advanced age, obesity, organ dysfunction (renal, hepatic), sepsis, burns, major trauma, hypoalbuminemia, and the use of extracorporeal therapies. Polypharmacy and drug-drug interactions further complicate therapeutic management. Recognizing these risk factors allows clinicians to identify patients who may benefit most from exposure-guided dose optimization.

Clinical Features

Clinically, inadequate drug exposure may manifest as persistent infection, treatment failure, adverse drug reactions, or unexpected toxicity. For example, subtherapeutic antibiotic levels can lead to non-resolving sepsis or the emergence of resistant organisms, while overdosing of sedatives or anticoagulants can result in delirium, bleeding, or prolonged mechanical ventilation. Early identification of at-risk patients and clinical vigilance are essential components of successful exposure-guided dosing strategies.

Diagnosis

Exposure-guided dose optimization relies on the measurement or estimation of drug concentrations therapeutic drug monitoring (TDM) combined with PK/PD modeling. Diagnostic tools include high-performance liquid chromatography, mass spectrometry, and immunoassays for drug quantification, as well as software for Bayesian forecasting and adaptive dosing. Interpretation of results requires integration of clinical status, timing of sample collection, and knowledge of drug-specific PK/PD targets, such as minimum inhibitory concentrations (MIC) for antibiotics or area under the curve (AUC) for anticoagulants.

Treatment & Management

The implementation of exposure-guided dosing involves several steps: identifying patients at risk, selecting appropriate drugs for TDM, collecting and analyzing samples, and adjusting doses based on PK/PD targets. This approach is most established for antimicrobials (e.g., vancomycin, aminoglycosides, beta-lactams), antiepileptics, and immunosuppressants. Multidisciplinary collaboration pharmacists, clinicians, laboratory staff is key for timely and effective dose adjustment. Protocols should ensure rapid turnaround of drug levels and integrate clinical decision support tools for dose calculations.

Recent Advances / Emerging Therapies

Recent advances in exposure-guided dose optimization include the integration of real-time TDM, point-of-care testing, and artificial intelligence-driven dosing algorithms. Population PK models and machine learning tools are increasingly used to predict drug exposure and recommend individualized dosing regimens. Novel biomarkers, such as procalcitonin for infection severity, can further refine dosing strategies. The use of closed-loop infusion systems and pharmacogenomics holds promise for expanding the scope of exposure-guided optimization in acute care.

Guideline Recommendations

International guidelines, including those from the Infectious Diseases Society of America (IDSA) and the Surviving Sepsis Campaign, advocate for exposure-guided dosing of critical antimicrobials in severe infections. The American Society of Health-System Pharmacists and other professional bodies recommend routine TDM for drugs with narrow therapeutic indices or high inter-patient variability. Guidelines emphasize the importance of multidisciplinary teams, standardized protocols, and continuous education to ensure safe and effective implementation.

Conclusion

Exposure-guided dose optimization represents a paradigm shift in the management of complex acute care patients, offering the potential to improve outcomes through individualized therapy. By integrating PK/PD principles, advanced monitoring technologies, and guideline-driven protocols, clinicians can address the challenges posed by critical illness and heterogeneous patient populations. Ongoing research and technological innovation are expected to further enhance the precision and feasibility of this approach, making it an essential component of modern acute care pharmacotherapy.